Biography
Kimberley S. Mak, MD, MPH, is an Associate Professor of Radiation Oncology at the Chobanian and Avedisian School of Medicine and its affiliate Boston Medical Center (BMC). She received her MPH from Harvard School of Public Health, MD from Harvard Medical School, and AB summa cum laude in Biochemical Sciences from Harvard College. Dr. Mak completed an internship in Internal Medicine at Brigham and Women's Hospital, followed by residency in the Harvard Radiation Oncology Program, training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital of Boston, and BMC. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology.
Dr. Mak's specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies. She speaks English and Cantonese. As Clinical Director of the Department of Radiation Oncology at BMC, she spearheaded quality improvement efforts leading to BMC becoming the first site in Massachusetts to achieve accreditation through the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence (APEx). She further analyzes quality metrics as Cancer Liaison Physician for the BMC Cancer Care Committee/American College of Surgeons Commission on Cancer.
Dr. Mak's research interests include patient-reported outcomes including quality of life and treatment toxicities; disparity outcomes research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; translational research; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work. Dr. Mak serves on multiple committees for ASTRO and the international cooperative research group, NRG Oncology. She has contributed her expertise in working groups for the National Quality Forum, Lung Cancer 360 and International Consortium for Health Outcomes Measurement.